Get startedLog in
    Picture of Theratechnologies logo

    TH — Theratechnologies News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapTurnaround
    All News

    Brief: Open Letter To Shareholders From CEO Paul Levesque

    Picture of Theratechnologies logoTheratechnologies
    04/01/2023 13:02
    Jan 4 (Reuters) - Theratechnologies Inc  TH.TO :
    * OPEN LETTER TO SHAREHOLDERS FROM CEO PAUL LEVESQUE
    * THERATECHNOLOGIES INC - OPEN LETTER TO SHAREHOLDERS FROM
CEO
PAUL LEVESQUE
    * THERATECHNOLOGIES INC: FY2023 REVENUE GUIDANCE RANGE SET
BETWEEN
$90 MILLION AND $95 MILLION
    * THERATECHNOLOGIES INC: FY2023 OPERATING PLAN TO FOCUS ON
ACHIEVING POSITIVE EBITDA IN NEAR-TERM
    * THERATECHNOLOGIES INC - SCIENTIFIC ADVISORY COMMITTEE
FORMED TO
OPTIMIZE PROTOCOL AMENDMENT FOR OUR PHASE 1 CLINICAL TRIAL OF
TH1902
    * THERATECHNOLOGIES INC - U.S. FOOD AND DRUG ADMINISTRATION
("FDA") CONFIRMED THEY WILL REVIEW PROTOCOL AMENDMENT WITHIN
THIRTY DAYS OF SUBMISSION
    * THERATECHNOLOGIES INC - FY2022 TOP LINE REVENUE EXPECTED
TO END
YEAR AT ABOUT $80 MILLION

Source text for Eikon:  ID:nGNX7pn4m4 
Further company coverage:  TH.TO 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Theratechnologies

    See all news